DENVER (July 7, 2020)—Perkins Coie represented New Jersey-based pharmaceuticals company, Pacira Biosciences, Inc., in its $402-million offering of convertible senior notes in a private placement pursuant to Rule 144A under the Securities Act of 1933.

The Firmwide Chair of Perkins Coie’s Corporate Practice, Jason Day, led the firm’s deal team which also included Denver-based partner Ned Prusse and counsel Jonathan Schulman, Seattle-based partner Eric DeJong, and associates Christopher Wassman and Cassandra Wetzel.

Pacira BioSciences is a top provider of regenerative health treatments and non-opioid pain management committed to improving and advancing outcomes for healthcare practitioners and their patients.

Perkins Coie is a leading international law firm that is known for providing high-value, strategic solutions and extraordinary client service on matters vital to our clients’ success. With more than 1,200 lawyers in offices across the United States and Asia, we provide a full array of corporate, commercial litigation, intellectual property, and regulatory legal advice to a broad range of clients, including many of the world’s most innovative companies and industry leaders as well as public and not-for-profit organizations.

Media Inquiries: Please email Justin Cole, Head of Media Relations.